RecruitingNCT05376046

Study of Erythrocyte Parameters and Hypercoagulability in Sickle Cell Disease (SCD-TGA)

Study of Erythrocyte Parameters and Hypercoagulability in Sickle Cell Disease


Sponsor

BILLOIR

Enrollment

200 participants

Start Date

Sep 1, 2018

Study Type

OBSERVATIONAL

Conditions

Summary

Sickle cell disease (SCD) is an inherited haemoglobinopathy disorder caused by mutations in HBB gene with amino-acid substitution on β globin chain. The consequence is synthesis of altered haemoglobin S (HbS) which polymerises in red blood cell (RBC) at deoxygenated state. SCD is associated with chronic haemolytic anaemia, vaso-occlusive crisis (VOC) leading to frequent hospitalisation. The aim of the study was to to investigate whether a combination of routine laboratory biomarkers of haemolysis could be used to predict VOC development in confirmed SCD patients.


Eligibility

Min Age: 18 Years

Inclusion Criteria1

  • Sickle cell disease

Exclusion Criteria3

  • <18 years
  • pregnancy
  • Patient under protective guardianship or curatorship

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

BIOLOGICALErythrocytic parameters and thrombin generation assay measurement

Erythrocytic parameters and thrombin generation assay measurement


Locations(1)

Rouen university Hospital

Rouen, France

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05376046


Related Trials